Turkish myelofibrosis Patients' treatment patterns revealed in new study
NCT ID NCT07357441
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed medical records of 355 people in Turkey with myelofibrosis (a type of bone marrow cancer) who were treated with the drug ruxolitinib for at least 3 months. Researchers collected information on patient demographics, disease characteristics, and how the drug was used in everyday practice between 2015 and 2022. The goal was to better understand real-world treatment patterns and patient outcomes in Turkey.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
- Can a new pill tame myelofibrosis?
- MRI as a window into bone marrow disease: a new biomarker test?
- Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
- Can a drug free myelofibrosis patients from frequent blood transfusions?
- Heart safety check for new myelofibrosis drug in healthy volunteers